Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.

MLA

Chua, Ming Jang, et al. “Effect of Clinically Approved HDAC Inhibitors on Plasmodium, Leishmania and Schistosoma Parasite Growth.” International Journal for Parasitology: Drugs & Drug Resistance, vol. 7, no. 1, Apr. 2017, pp. 42–50. EBSCOhost, https://doi.org/10.1016/j.ijpddr.2016.12.005.

APA

Chua, M. J., Arnold, M. S. J., Xu, W., Lancelot, J., Lamotte, S., Späth, G. F., Prina, E., Pierce, R. J., Fairlie, D. P., Skinner-Adams, T. S., & Andrews, K. T. (2017). Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. International Journal for Parasitology: Drugs & Drug Resistance, 7(1), 42–50. https://doi.org/10.1016/j.ijpddr.2016.12.005

Chicago

Chua, Ming Jang, Megan S.J. Arnold, Weijun Xu, Julien Lancelot, Suzanne Lamotte, Gerald F. Späth, Eric Prina, et al. 2017. “Effect of Clinically Approved HDAC Inhibitors on Plasmodium, Leishmania and Schistosoma Parasite Growth.” International Journal for Parasitology: Drugs & Drug Resistance 7 (1): 42–50. doi:10.1016/j.ijpddr.2016.12.005.